Several pharmaceutical companies showcased data on their BTK inhibitors at the ASCO 2023 conference, including Ono ...

NRIX stock is rated Strong Buy as bexobrutideg advances in CLL trials. See here for NRIX stock's milestones, market potential ...

The U.S. Food and Drug Administration (FDA) has granted fast track designation to UB-VV111 for the treatment of ...

Acalabrutinib plus obinutuzumab shows superior long-term outcomes in treatment-naive chronic lymphocytic leukemia.

Recent developments in the treatment of chronic lymphocytic leukemia (CLL) have included a fixed-duration oral combination regimen for untreated patients and promising results with a Bruton's tyrosine ...

Personalized exercise guidance is needed for people living with Chronic Lymphocytic Leukemia (CLL), the most common type of blood cancer, according to a new study led by the University of Surrey. The ...

Analysis of readmission rates, length of stay and mortality among bone marrow transplant and CAR-T patients in a rural state. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This ...

Nanopore sequencing offers comparable accuracy to short-read NGS for IGH clonotyping in CLL, with advantages in cost and laboratory footprint. The study confirms reliable somatic hypermutation status ...

Researchers at Weill Cornell Medicine and the University of Adelaide have developed GoT-Multi, a tool that tracks multiple ...

CD5-deleted chimeric antigen receptor cells (Senza5 CART5) to enhance immunotherapy against T-cell non-Hodgkin lymphoma: A first-in-human phase I clinical trial (NCT06420089). This is an ASCO Meeting ...